Compare Incyte Corporation (INCY) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SpaceX — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while SpaceX trades at $126.91 (market cap $1.58T). The key difference: SpaceX is far larger — about 68.4× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals.
| INCY | SPCX | |
|---|---|---|
Market Cap | $23.11B | $1.58T |
Sector | Health | Technology |
52-Week High | $118.52 | $202.09 |
52-Week Low | $67.38 | $119.85 |
Enterprise Value | $19.13B | $1.59T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SPCX trades at $119.85, down 3.34% today and 45% below its post-IPO high, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 EPS of -$1.19, missing estimates by 260%, while revenue grew to $18.67B in 2025. SpaceX faces significant valuation concerns with a P/S of 84 and negative profitability metrics, though analyst consensus remains 100% buy-rated with a $237.78 price target representing 98% upside potential.
The stock presents high-risk/high-reward potential with strong institutional support but faces near-term headwinds from August lockup expirations and persistent losses. Long-term growth depends on Starlink expansion and AI contract wins, though current fundamentals don't justify the premium valuation. Investors must weigh analyst optimism against cash burn and execution risks in the competitive space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
